Mirum Pharmaceuticals, Inc. (MIRM)
NASDAQ: MIRM · Real-Time Price · USD
68.14
+0.42 (0.62%)
At close: Nov 7, 2025, 4:00 PM EST
68.11
-0.03 (-0.04%)
After-hours: Nov 7, 2025, 4:20 PM EST
Mirum Pharmaceuticals Stock Forecast
Stock Price Forecast
The 12 analysts that cover Mirum Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $81.58, which forecasts a 19.72% increase in the stock price over the next year. The lowest target is $55 and the highest is $95.
Price Target: $81.58 (+19.72%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Mirum Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 6 | 6 | 6 |
| Buy | 7 | 7 | 4 | 5 | 6 | 6 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 9 | 11 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $85 → $95 | Buy | Maintains | $85 → $95 | +39.42% | Nov 5, 2025 |
| Citizens | Citizens | Buy Maintains $81 → $95 | Buy | Maintains | $81 → $95 | +39.42% | Nov 5, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $80 → $81 | Strong Buy | Maintains | $80 → $81 | +18.87% | Nov 5, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $75 → $81 | Buy | Maintains | $75 → $81 | +18.87% | Oct 16, 2025 |
| TD Cowen | TD Cowen | Strong Buy Initiates $95 | Strong Buy | Initiates | $95 | +39.42% | Sep 24, 2025 |
Financial Forecast
Revenue This Year
515.92M
from 336.89M
Increased by 53.14%
Revenue Next Year
618.23M
from 515.92M
Increased by 19.83%
EPS This Year
-0.70
from -1.85
EPS Next Year
0.01
from -0.70
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 546.0M | 685.7M | |||
| Avg | 515.9M | 618.2M | |||
| Low | 482.2M | 554.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 62.1% | 32.9% | |||
| Avg | 53.1% | 19.8% | |||
| Low | 43.1% | 7.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.30 | 0.82 | |||
| Avg | -0.70 | 0.01 | |||
| Low | -1.13 | -0.78 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.